The estimated Net Worth of Howland Shaw Warren is at least $1.11 Milhão dollars as of 25 April 2006. Howland Warren owns over 8,000 units of Cortexyme Inc stock worth over $437,970 and over the last 21 years Howland sold CRTX stock worth over $673,760.
Howland has made over 16 trades of the Cortexyme Inc stock since 2003, according to the Form 4 filled with the SEC. Most recently Howland sold 8,000 units of CRTX stock worth $41,920 on 25 April 2006.
The largest trade Howland's ever made was exercising 21,356 units of Cortexyme Inc stock on 6 April 2006 worth over $22,424. On average, Howland trades about 8,206 units every 48 days since 2003. As of 25 April 2006 Howland still owns at least 224,600 units of Cortexyme Inc stock.
You can see the complete history of Howland Warren stock trades at the bottom of the page.
Howland's mailing address filed with the SEC is C/O CRITICAL THERAPEUTICS, INC., 60 WESTVIEW STREET, LEXINGTON, MA, 02421.
Over the last 21 years, insiders at Cortexyme Inc have traded over $59,595,534 worth of Cortexyme Inc stock and bought 19,273,711 units worth $164,053,955 . The most active insiders traders include & Johnson Johnson & Johnson..., Farmaceutici Sp A Chiesi, eAnsbert Gadicke. On average, Cortexyme Inc executives and independent directors trade stock every 59 days with the average trade being worth of $475,426. The most recent stock trade was executed by Caryn Gordon Mc Dowell on 6 June 2022, trading 10,800 units of CRTX stock currently worth $30,888.
Cortexyme, Inc. is a clinical stage biopharmaceutical company pioneering upstream therapeutic approaches designed to improve the lives of patients diagnosed with Alzheimer's and other degenerative diseases. Based upon the evidence generated to date, Cortexyme is currently advancing its lead therapeutic candidate, atuzaginstat (COR388), in the GAIN Trial, an ongoing Phase 2/3 clinical trial in patients with mild to moderate Alzheimer's disease. Cortexyme is targeting a specific, infectious pathogen found in the brain and other organs and tied to degeneration and inflammation in humans and animal models.
Cortexyme Inc executives and other stock owners filed with the SEC include: